Literature DB >> 22951471

Gene therapy to mitigate radiation-induced bone marrow aplasia: preliminary study in highly irradiated monkeys.

Michel Drouet1, Diane Agay, Philippe Garrigou, André Peinnequin, Francis Hérodin.   

Abstract

The hematopoietic syndrome represents the first therapeutic challenge following exposure to high doses of ionizing radiation. Today there is a crucial need to identify/develop new treatments in order to reach the transplantation threshold. The authors propose the concept of a global niche therapy strategy based on local and short-term secretion of selected morphogenes to favor a vascular niche in order to raise the transplantation threshold regeneration and to stimulate residual hematopoietic stem and progenitor cells. The present study was aimed at setting up a monkey model of gene therapy using Sonic hedgehog (Shh) as a first candidate. Multipotent mesenchymal stem cells from adipocyte tissues were nucleofected with mock and Sonic hedgehog pIRES2 plasmids using Amaxa technology. 8-Gy gamma irradiated monkeys were given a single intraosseous injection of manipulated or unmanipulated adipocyte stem cells 48 h following total body irradiation. Mock and Shh-grafts were well tolerated. This preliminary study establishes the feasibility of transient gene therapy in highly irradiated monkeys. Ongoing studies will determine the putative efficacy of this therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22951471     DOI: 10.1097/HP.0b013e3182475a93

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  2 in total

1.  Short-term sonic-hedgehog gene therapy to mitigate myelosuppression in highly irradiated monkeys: hype or reality?

Authors:  M Drouet; P Garrigou; A Peinnequin; F Hérodin
Journal:  Bone Marrow Transplant       Date:  2013-10-28       Impact factor: 5.483

Review 2.  Hematopoietic Stem Cells and Mesenchymal Stromal Cells in Acute Radiation Syndrome.

Authors:  Liren Qian; Jian Cen
Journal:  Oxid Med Cell Longev       Date:  2020-08-08       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.